Company Profile: MIRA Pharmaceuticals, Inc.

Background

Overview

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical development company specializing in neuroscience, focusing on innovative treatments for various neurologic and neuropsychiatric disorders. Established in 2020, the company is headquartered in Miami, Florida. MIRA Pharmaceuticals is publicly traded on the NASDAQ under the ticker symbol MIRA.

Mission and Vision

MIRA Pharmaceuticals is dedicated to advancing the treatment of complex neurological conditions by developing novel therapies that address unmet medical needs. The company's vision is to improve patient outcomes through innovative, evidence-based treatments that enhance quality of life.

Primary Area of Focus

The company's primary focus is on the development of oral pharmaceutical therapies targeting conditions such as treatment-resistant depression, major depressive disorder with suicidal ideation, post-traumatic stress disorder, anxiety, and cognitive decline associated with early-stage dementia.

Industry Significance

Operating within the biotechnology and pharmaceutical sectors, MIRA Pharmaceuticals contributes to the advancement of mental health treatments, an area with significant unmet needs. The company's innovative approach positions it as a potential leader in developing next-generation therapies for complex neuropsychiatric disorders.

Key Strategic Focus

Core Objectives

Development of Novel Therapies: Focus on creating innovative treatments for neurological and psychiatric conditions.

Clinical Advancement: Progress pipeline candidates through clinical trials to achieve regulatory approvals.

Market Expansion: Extend the reach of therapies to global markets, addressing widespread health challenges.

Specific Areas of Specialization

Neuropsychiatric Disorders: Targeting conditions such as depression, PTSD, anxiety, and cognitive decline.

Oral Pharmaceutical Development: Emphasis on developing oral medications for ease of administration and patient compliance.

Key Technologies Utilized

Pharmacogenomics: Employing genetic information to guide drug development and personalized treatment strategies.

Advanced Drug Formulation: Utilizing cutting-edge techniques to enhance drug efficacy and bioavailability.

Primary Markets Targeted

United States: Primary market for initial product launches and clinical trials.

Canada and Mexico: Secured exclusive rights for certain products, aiming for market penetration in these regions.

Financials and Funding

Funding History

MIRA Pharmaceuticals has engaged in multiple funding rounds to support its research and development efforts. Notably, in August 2023, the company went public through an initial public offering (IPO) on the NASDAQ, raising capital to advance its clinical programs.

Total Funds Raised

The exact total funds raised by MIRA Pharmaceuticals are not publicly disclosed. However, the IPO in August 2023 was a significant milestone in the company's funding history.

Notable Investors

Specific details about individual investors are not publicly available. The IPO attracted a diverse group of institutional and individual investors interested in the company's innovative approach to treating neuropsychiatric disorders.

Intended Utilization of Capital

The capital raised is primarily allocated towards:

Clinical Trials: Funding ongoing and upcoming clinical studies for pipeline candidates.

Research and Development: Enhancing drug discovery and development processes.

Operational Expansion: Scaling operations to support commercialization efforts.

Pipeline Development

Key Pipeline Candidates

1. Ketamir-2: A novel, patent-pending oral ketamine analog under investigation for treating neuropathic pain, treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.

2. MIRA-55: An oral pharmaceutical marijuana analog being developed for treating adult patients suffering from anxiety and cognitive decline associated with early-stage dementia.

Stages of Clinical Trials

Ketamir-2: The company has initiated Phase 1 clinical trials in Israel, with expected completion by Q4 2025.

MIRA-55: Currently in preclinical development, with plans to advance into clinical trials upon successful preclinical outcomes.

Target Conditions

Ketamir-2: Neuropathic pain, treatment-resistant depression, major depressive disorder with suicidal ideation, post-traumatic stress disorder.

MIRA-55: Anxiety, cognitive decline associated with early-stage dementia.

Relevant Timelines for Anticipated Milestones

Ketamir-2: Completion of Phase 1 trials by Q4 2025, with potential progression to Phase 2 trials in 2026.

MIRA-55: Advancement into clinical trials contingent upon successful preclinical results, with timelines to be determined.

Technological Platform and Innovation

Proprietary Technologies

Ketamir-2: A unique oral ketamine analog designed to provide rapid antidepressant effects with a favorable safety profile.

MIRA-55: An innovative oral pharmaceutical marijuana analog aimed at treating anxiety and cognitive decline.

Significant Scientific Methods

Clinical Pharmacology: Utilizing advanced pharmacokinetic and pharmacodynamic modeling to optimize drug dosing and efficacy.

Biomarker Development: Identifying and validating biomarkers to guide patient selection and monitor treatment response.

Leadership Team

Executive Profiles

Erez Aminov: Chief Executive Officer and Chairman. Brings extensive experience in pharmaceutical development and corporate leadership.

Alan Weichselbaum, CPA, M.B.A.: Chief Financial Officer. Provides financial oversight and strategic guidance, leveraging a strong background in finance and accounting.

Dr. Itzchak Angel, Ph.D.: Chief Scientific Advisor. Offers scientific expertise, particularly in the areas of pharmacology and neuroscience.

Competitor Profile

Market Insights and Dynamics

The pharmaceutical industry, particularly in the field of neuropsychiatric disorders, is characterized by high unmet medical needs and significant competition. Companies are striving to develop effective treatments for conditions with limited therapeutic options.

Competitor Analysis

AstraZeneca plc: A global biopharmaceutical company with a strong presence in neurology, particularly in treatments for neurological diseases such as multiple sclerosis and Alzheimer's.

Biogen Inc.: Specializes in neurology, focusing on treatments for neurological diseases, including multiple sclerosis and Alzheimer's.

Regeneron Pharmaceuticals: Offers a wide array of therapeutic offerings, including treatments for eye diseases and oncology, competing in the neuropsychiatric space.

Strategic Collaborations and Partnerships

MIRA Pharmaceuticals has engaged in strategic partnerships to enhance its research and development capabilities, including a proposed acquisition of SKNY Pharmaceuticals to expand its pipeline.

Operational Insights

MIRA Pharmaceuticals differentiates itself through its focus on oral formulations for rapid onset of action and patient compliance, aiming to provide accessible and effective treatments for complex neuropsychiatric conditions.

Strategic Opportunities and Future Directions

The company plans to advance its pipeline candidates through clinical trials, seek strategic partnerships for commercialization, and explore additional indications to broaden its therapeutic impact.